CN102008504A - Blood plasma product for clinical transfusion and preparation method thereof - Google Patents
Blood plasma product for clinical transfusion and preparation method thereof Download PDFInfo
- Publication number
- CN102008504A CN102008504A CN2010105777009A CN201010577700A CN102008504A CN 102008504 A CN102008504 A CN 102008504A CN 2010105777009 A CN2010105777009 A CN 2010105777009A CN 201010577700 A CN201010577700 A CN 201010577700A CN 102008504 A CN102008504 A CN 102008504A
- Authority
- CN
- China
- Prior art keywords
- blood
- blood plasma
- transfusion
- cord
- clinical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a blood plasma product for clinical transfusion and a preparation method thereof. The blood plasma product is prepared from cord blood. The preparation method is as follows: the cord blood in placeta umbilic, which is wasted from a term birth infant, is collected and is centrifuged, and nucleated cells are removed; ABO and Rh blood type detection, blood cell and blood plasma component measurement, pathogenic microorganism immunoassay and germiculture are carried out on the obtained blood plasma without the nucleated cells; and qualified blood plasma is detected, a proper amount of protective agent is added, spin-freeze is carried out at the temperature of minus 35 DEG C for 2 hours, and then freeze-drying is carried out at the temperature of 35 DEG C-37 DEG C within 18-20 hours to obtain the freeze-dried cord blood plasma product. The transfusion comprises common clinical transfusion and transfusion in the aspects of malignant tumor subject to chemo-treatment/radiation treatment and poor hematopoiesis diseases caused by aplastic anemia. The cord blood is a special transfusion resource with important treatment function and also a source of important candidate stem cells.
Description
Technical field
The present invention relates to a kind of blood plasma product and preparation method thereof, especially a kind of derive from Cord blood be used for blood plasma product of clinical blood transfusion and preparation method thereof.
Background technology
As everyone knows, blood is to save the indispensable material of some critical patient's life.The work of China's voluntary blood donation has in recent years obtained remarkable progress, but in general, breach is still very big between China's blood demand and the supply, nearly 1000 tons of annual blood using amount, and voluntary blood donation can only be satisfied the blood using amount less than 30%.Being in an emergency and happening occasionally in the blood source, still needs import to meet clinical needs.
Cord blood is to residue in umbilical cord and intraplacental blood behind the disconnected umbilicus of neonate birth.Oneself becomes a kind of important hematopoietic stem cell source that is used for clinical transplantation Cord blood.Because wherein competent cell and molecule composition are higher than adult's blood or for the blood of being grown up is not had, in recent years the Cord blood infusion after malignant tumorization/radiotherapy and the aspects such as Supporting Therapy of the short hemopoietic treatment of HD disease such as aplastic anemia, anti-infective therapy, immunization therapy, serious disease obtained challenging effect.
Summary of the invention
Technical problem to be solved by this invention is, provide a kind of derive from Cord blood be used for blood plasma product of clinical blood transfusion and preparation method thereof.
In order to solve the problems of the technologies described above, the technical solution used in the present invention is: a kind of blood plasma product that is used for clinical blood transfusion, it is prepared by Cord blood.
The described preparation method that is used for the blood plasma product of clinical blood transfusion comprises the steps:
(1) Cord blood of the depleted Placenta Hominis umbilical cord of collection term labor baby is centrifugal, removes nucleated cell;
(2) go gained blood plasma to carry out ABO and the detection of Rh blood group, hemocyte and blood plasma components mensuration, pathogenic microorganism immune detection and antibacterial culturing;
(3) detect qualified blood plasma, add an amount of protective agent, revolve under-35 ℃ and freeze, after 2 hours, under 35 ℃-37 ℃, cold dry-cure in the 18-20 hour, obtain lyophilizing Cord blood slurry formulation.
After described blood transfusion comprises common clinical blood transfusion and is used for malignant tumorization/radiotherapy and the blood transfusion of the Supporting Therapy aspect of the short hemopoietic treatment of aplastic anemia HD disease, anti-infective therapy, immunization therapy, serious disease.
The invention has the beneficial effects as follows: Cord blood also is a kind of special blood resource with critical treatment effect except being a kind of important hematopoietic stem cell source, and it is with a wide range of applications in clinical.
The specific embodiment
Below in conjunction with the specific embodiment the present invention is described in further detail:
The blood plasma product that is used for clinical blood transfusion of the present invention, it is prepared by Cord blood.
The described preparation method that is used for the blood plasma product of clinical blood transfusion comprises the steps:
(1) Cord blood of the depleted Placenta Hominis umbilical cord of collection term labor baby is centrifugal, removes nucleated cell;
(2) go gained blood plasma to carry out ABO and the detection of Rh blood group, hemocyte and blood plasma components mensuration, pathogenic microorganism immune detection and antibacterial culturing;
(3) detect qualified blood plasma, add an amount of protective agent, revolve under-35 ℃ and freeze, after 2 hours, under 35 ℃-37 ℃, cold dry-cure in the 18-20 hour, obtain lyophilizing Cord blood slurry formulation.
After described blood transfusion comprises common clinical blood transfusion and is used for malignant tumorization/radiotherapy and the blood transfusion of the Supporting Therapy aspect of the short hemopoietic treatment of aplastic anemia HD disease, anti-infective therapy, immunization therapy, serious disease.
Cord blood cell is longer than the adult blood cell survival, and various hemopoietic growth factors are several times of normal level even higher in the cord blood plasma, and the Cord blood infusion can stimulate normal hematopoiesis.Cord blood infusion obviously ameliorate tumor is put/bone marrow depression degree after the chemotherapy, reduce the bone marrow depression phase, thereby reduce complication, improve overall survival rate, and cord blood plasma can inducing leukemia cell enter proliferating cycle, strengthen the sensitivity of leukaemia to chemotherapy.Chemotherapy combined Cord blood infusion can improve leukemic remission rate.
Chronic aplastic anemia (CAA) patient gives can obviously improve its peripheral hemogram behind the Cord blood infusion, the myeloid progenitor level that raises rapidly, and blood plasma colony stimulating activity and quick-fried formula colony stimulating activity that pathologic is raise recover normal.Cord blood infusion and Drug therapy are united CAA are had cooperative effect, can reduce drug dose and shorten the course of treatment, and can reduce the dependence to blood transfusion.
Contain multiple micromolecule polypeptide in the cord blood plasma, have immunostimulant and immunoregulation effect, can increase total complement level in the serum, promote the phagocyte phagocytosis, improve the human peripheral blood leucocyte level.Contain a large amount of immunoglobulins in the umbilical blood, therefore, it has very strong immunocompetence.Content of hemoglobin height in the umbilical blood has affinity highly to oxygen, helps improving anoxia and the related symptoms that anemia causes.Umbilical blood and cord blood plasma infusion have good Supporting Therapy and non-specific wide spectrum anti-infectious function, help strengthening the physical function and the resistance of patient with severe symptoms and infected patient, promote the control of disease.
Therefore, Cord blood except be-kind of important hematopoietic stem cell source, also be a kind of special blood resource with critical treatment effect, it is with a wide range of applications in clinical.
In sum, content of the present invention is not limited in the above-described embodiment, and the knowledgeable people in the same area can propose other embodiment easily within technological guidance's thought of the present invention, but this embodiment comprises within the scope of the present invention.
Claims (3)
1. a blood plasma product that is used for clinical blood transfusion is characterized in that, it is prepared by Cord blood.
2. be used for the preparation method of the blood plasma product of clinical blood transfusion according to claim 1, it is characterized in that, comprise the steps:
(1) Cord blood of the depleted Placenta Hominis umbilical cord of collection term labor baby is centrifugal, removes nucleated cell;
(2) go gained blood plasma to carry out ABO and the detection of Rh blood group, hemocyte and blood plasma components mensuration, pathogenic microorganism immune detection and antibacterial culturing;
(3) detect qualified blood plasma, add an amount of protective agent, revolve under-35 ℃ and freeze, after 2 hours, under 35 ℃-37 ℃, cold dry-cure in the 18-20 hour, obtain lyophilizing Cord blood slurry formulation.
3. the blood plasma product that is used for clinical blood transfusion according to claim 1, it is characterized in that, after described blood transfusion comprises common clinical blood transfusion and is used for malignant tumorization/radiotherapy and the blood transfusion of the Supporting Therapy aspect of the short hemopoietic treatment of aplastic anemia HD disease, anti-infective therapy, immunization therapy, serious disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105777009A CN102008504A (en) | 2010-12-09 | 2010-12-09 | Blood plasma product for clinical transfusion and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105777009A CN102008504A (en) | 2010-12-09 | 2010-12-09 | Blood plasma product for clinical transfusion and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102008504A true CN102008504A (en) | 2011-04-13 |
Family
ID=43838966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105777009A Pending CN102008504A (en) | 2010-12-09 | 2010-12-09 | Blood plasma product for clinical transfusion and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102008504A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102250838A (en) * | 2011-06-04 | 2011-11-23 | 内蒙古医学院 | Clinical and experimental foreign protein-free stem cell culture medium additive and application thereof |
| CN109679889A (en) * | 2018-12-28 | 2019-04-26 | 英科博雅生命科技有限公司 | The preparation method of cord blood plasma Essence or its freeze dried powder |
| JP2019523281A (en) * | 2016-08-01 | 2019-08-22 | エンブリオジェネシス ピーティーワイ リミテッド | Skin care formulation |
| US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
-
2010
- 2010-12-09 CN CN2010105777009A patent/CN102008504A/en active Pending
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102250838A (en) * | 2011-06-04 | 2011-11-23 | 内蒙古医学院 | Clinical and experimental foreign protein-free stem cell culture medium additive and application thereof |
| CN102250838B (en) * | 2011-06-04 | 2014-03-19 | 内蒙古医学院 | Clinical and experimental foreign protein-free stem cell culture medium additive and application thereof |
| JP2019523281A (en) * | 2016-08-01 | 2019-08-22 | エンブリオジェネシス ピーティーワイ リミテッド | Skin care formulation |
| US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
| CN109679889A (en) * | 2018-12-28 | 2019-04-26 | 英科博雅生命科技有限公司 | The preparation method of cord blood plasma Essence or its freeze dried powder |
| CN109679889B (en) * | 2018-12-28 | 2022-06-24 | 英科博雅生命科技有限公司 | Preparation method of cord blood plasma essence or freeze-dried powder thereof |
| US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
| US11609042B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
| US11740019B2 (en) | 2019-03-14 | 2023-08-29 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11747082B2 (en) | 2019-03-14 | 2023-09-05 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
| US11815311B2 (en) | 2019-03-14 | 2023-11-14 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Le Thi Bich et al. | Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study | |
| Ozaki Tan et al. | Novel applications of mesenchymal stem cell-derived exosomes for myocardial infarction therapeutics | |
| CN102008504A (en) | Blood plasma product for clinical transfusion and preparation method thereof | |
| US11160834B2 (en) | Scalable production of standardized extracellular vesicles, extracellular vesicle preparations and uses thereof | |
| US20210346281A1 (en) | Multi-component injection | |
| Wang et al. | Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus | |
| WO2018106984A1 (en) | Markers for personalized cancer treatment with lsd1 inhibitors | |
| Abbaspanah et al. | Applications of umbilical cord derived mesenchymal stem cells in autoimmune and immunological disorders: from literature to clinical practice | |
| EP2510926B1 (en) | Use of saturated amines compounds in manufacture of medicaments for mobilizing peripheral blood hematopoietic stem cell | |
| WO2014094546A1 (en) | Use of fusion protein | |
| Chen et al. | Role of bone marrow mesenchymal stem cells in the development of PQ‑induced pulmonary fibrosis | |
| CN103013914B (en) | Method for in-vitro culture of killer T cells | |
| Han et al. | Biological character of RetroNectin activated cytokine-induced killer cells | |
| CN113577070A (en) | Combined pharmaceutical composition for treating acute myeloid leukemia and application thereof | |
| Takami et al. | Novel findings for the development of drug therapy for various liver diseases: Current state and future prospects for our liver regeneration therapy using autologous bone marrow cells for decompensated liver cirrhosis patients | |
| CN101914497A (en) | Clinical N-CIK cell culture and quality control and identification kit and application | |
| Gotts et al. | Cell-based therapy in sepsis. A step closer | |
| Nio et al. | Cytotoxic and cytostatic effects of the streptococcal preparation OK‐432 and its subcellular fractions on human ovarian tumor cells | |
| CN109602745B (en) | Application of 2-indole carboxamide compound in preparation of anticancer drugs | |
| Lipton | Peripheral blood as a stem cell source for hematopoietic cell transplantation in children: is the effort in vein? | |
| Chen et al. | Combination of Cobe AutoPBSC and Gambro Elutra as a platform for monocyte enrichment in dendritic cell (DC) therapy: clinical study | |
| CN105168199A (en) | Application of curcumenol in preparing drug for performing targeted inhibiting on tumor cell EZH2 protein | |
| CN105136781A (en) | Applications of adipokine GREM2 in preparation of obesity treatment drugs | |
| CN1418633A (en) | Anti-cancer assistant medicine contg. 20(S)-protopanaxadiol as effective component, and its application | |
| CN103897050A (en) | Sepia anti-prostate cancer polypeptide and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110413 |